A systematic review of phase 3 trials indicates tirzepatide at 10-15 mg produces greater weight loss than semaglutide 2.4 mg with fewer side effects, aligning with anecdotal reports. Forum users note typical losses around 15% with sema and 20% with tirz, plus additional gains with newer agents, and several describe markedly less nausea when using tirzepatide or retatrutide.
What this discussion establishesNothing here is advice.
A systematic review showed tirzepatide at 10-15 mg produced more weight loss than semaglutide at its maximum 2.4 mg dose and also came with fewer side effects. This is the first academic source I have seen that backs up the social media reports from people who used both, specifically noting reduced side effects with tirzepatide.
Been assuming everyone already knew these figures. Sema comes in at fifteen percent, tirz at twenty, and reta between twenty four and twenty five.
I'd never encountered an academic reference before claiming this compound leads to milder negative reactions. Just today I came across another one repeating that same point.
After they analyzed everything about my situation thoroughly the results came out identical.
Although the conversation is outdated it aided my choice regarding upcoming peptides. At present I'm taking one but the persistent queasiness feels awful.
It looks like the GIP addition really cuts down on problems from what I notice. I've hit twenty four weeks total now after using Tirz the first four weeks before moving to Reta and went the whole stretch without any stomach trouble during my sixty pound drop.
Have you tried any other peps? If so, would you mind sharing your experience with side effects?
That's a solid discovery, I appreciate you putting this up.
I haven't tried KLOW myself. In my view, it's preferable to administer the peptides on their own. However, I experimented with cag, and it really packs a punch. When obtaining cag, balance the acidity properly, otherwise it can cause a sharp pain. At six foot two and two hundred pounds, I used half a milligram, and the initial two injections felt overwhelming. I can't recall the exact reason, but high amounts or extended use of cag isn't advised, so look into it yourself. For something that avoids an additional shot, tesofensine might be worth considering.
Yeah that could account for their research into raising the dosage of the drug to remain competitive. I never saw the outcome of those trials or if there was any link to pancreas issues. I figure approval after positive results would lead to nonstop television promotions.
Did they check the unwanted reaction details as well? In any case I see a systematic review as going through earlier experiment outcomes to form a clearer overall picture, which means more of those broad evaluations gives stronger grounds to rely on the findings.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.